Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Neumora Therapeutics, Inc.

Contributing Author

Recent Articles by Neumora Therapeutics, Inc.

Aug-14
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update NMRA -7.51% GlobeNewswire
Jul-27
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026 NMRA +11.41% GlobeNewswire
Jun-15
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update NMRA -48.62% GlobeNewswire
May-12
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference NMRA NMRA -6.32% GlobeNewswire
May-07
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update NMRA -16.74% GlobeNewswire
Apr-06
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference NMRA +6.00% GlobeNewswire
Mar-30
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update NMRA -17.17% GlobeNewswire
Mar-16
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 NMRA GlobeNewswire
Feb-04
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 NMRA GlobeNewswire
Jan-05
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones NMRA GlobeNewswire
Jan-05
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation NMRA GlobeNewswire
Nov-06
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire
Nov-03
Neumora Therapeutics to Participate in Upcoming Conferences in November NMRA GlobeNewswire
Oct-27
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 NMRA GlobeNewswire
Oct-27
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model NMRA GlobeNewswire
Oct-01
Neumora Therapeutics to Host Virtual R&D Day on October 27 NMRA GlobeNewswire
Sep-02
Neumora Therapeutics to Participate in Upcoming Conferences in September NMRA GlobeNewswire
Aug-06
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire
Jul-23
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 NMRA GlobeNewswire
Jul-09
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 NMRA +13.12% GlobeNewswire
May-12
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update NMRA GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)